223 related articles for article (PubMed ID: 33833221)
1. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer.
Liu H; Liang Z; Zhou C; Zeng Z; Wang F; Hu T; He X; Wu X; Wu X; Lan P
Signal Transduct Target Ther; 2021 Apr; 6(1):144. PubMed ID: 33833221
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
4. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
5. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
6. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
7. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.
Kikuchi H; Pino MS; Zeng M; Shirasawa S; Chung DC
Cancer Res; 2009 Nov; 69(21):8499-506. PubMed ID: 19843849
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.
Chun SY; Johnson C; Washburn JG; Cruz-Correa MR; Dang DT; Dang LH
Mol Cancer; 2010 Nov; 9():293. PubMed ID: 21073737
[TBL] [Abstract][Full Text] [Related]
10. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
11. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
Mi C; Cao X; Ma K; Wei M; Xu W; Lin Y; Zhang J; Wang TY
Chem Biol Interact; 2022 Jan; 351():109729. PubMed ID: 34717917
[TBL] [Abstract][Full Text] [Related]
12. SK4 oncochannels regulate calcium entry and promote cell migration in KRAS-mutated colorectal cancer.
Ibrahim S; Chaigne J; Dakik H; Fourbon Y; Corset L; Lecomte T; Raoul W; Guéguinou M
Cell Calcium; 2021 Jun; 96():102384. PubMed ID: 33676318
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
14. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
15. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
16. SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis.
Hu SS; Han Y; Tan TY; Chen H; Gao JW; Wang L; Yang MH; Zhao L; Wang YQ; Ding YQ; Wang S
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937641
[TBL] [Abstract][Full Text] [Related]
17. Adrenomedullin is a therapeutic target in colorectal cancer.
Wang L; Gala M; Yamamoto M; Pino MS; Kikuchi H; Shue DS; Shirasawa S; Austin TR; Lynch MP; Rueda BR; Zukerberg LR; Chung DC
Int J Cancer; 2014 May; 134(9):2041-50. PubMed ID: 24519534
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
19. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic
Cenigaonandia-Campillo A; Serna-Blasco R; Gómez-Ocabo L; Solanes-Casado S; Baños-Herraiz N; Puerto-Nevado LD; Cañas JA; Aceñero MJ; García-Foncillas J; Aguilera Ó
Theranostics; 2021; 11(8):3595-3606. PubMed ID: 33664850
[No Abstract] [Full Text] [Related]
20. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
